PRKG1 and Hyperglycemia: In Type I diabetic mice, CGA treatment increased cyclic GMP (cGMP) level and activated protein kinase G (PKG) in cardiac fibroblasts by enhancing eNOS activity and NO production, thereby contributing to the inhibition on cardiac fibrosis caused by hyperglycemia [40].